# MBX Biosciences (MBX) — Earnings

MBX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mbx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2024 |
| Period end | Dec 31, 2024 |
| EPS actual | −$0.47 |
| EPS estimate | −$0.57 |
| EPS surprise | +17.99% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Mar 17, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1776111/000095017025039837/mbx-20250317.htm) |

MBX Biosciences has a very short earnings record here: the table holds a single quarter. For Q4 2024, the period ended December 31, 2024, the company reported on March 17, 2025. It posted a loss of $0.47 per share, narrower than the $0.57 loss expected, a 17.99% beat. The source lists no revenue for the quarter, and no revenue estimate was given.

With only one quarter on record, there is no year-over-year comparison, no complete fiscal year and no trend to describe. The table also has no quarters after Q4 2024, so it does not show how results have developed since. It shows a quarterly loss that came in better than expected. Any reading of the company's direction from this single figure would go beyond what the data supports.

The table gives only one report date, so there is no reporting pattern to point to the timing of the next release. The Q4 2024 results came out about eleven weeks after the quarter ended. Newer quarters, once they appear, will show whether the company continues to report losses, how those losses compare with the $0.47 per share shown here, and whether any revenue is recorded.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2024 | Mar 17, 2025 | −$0.57 | −$0.47 | 17.99% | — | — |

## Frequently Asked Questions

### When did MBX Biosciences (MBX) last report earnings?

MBX Biosciences last reported on Mar 17, 2025, covering fiscal Q4 2024.

### Did MBX beat earnings estimates?

Yes. MBX Biosciences reported EPS of −$0.47 for Q4 2024 against a −$0.57 estimate — a 17.99% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).